

## UNC SON ECHO ABC for MOUD

Addiction and Behavioral Clinic for Medication for Opioid Use Disorder Treatment

# URINE DRUG SCREENING: PEARLS AND PITFALLS

MICHAEL BACA-ATLAS, MD, FASAM
UNC DEPARTMENT OF FAMILY MEDICINE
UNC WAKEBROOK PRIMARY CARE
1/27/23

UNC SON ECHO ABC for MOUD is made possible by funding from the Health Resources & Services Administration (HRSA) Grant numbers: T94HP30882 (2017-2023) and T14HP33207 (2019-2023)







# Disclosures

•I have nothing to disclose.









# Objectives

•Describe how to utilize drug screening in clinical practice.

•Review cases to highlight pearls and pitfalls of utilizing urine drug screens in primary care settings.

 Discuss strategies to engage patients in difficult conversations around discordant results.










# Role for Drug Testing

Figure 4. Percentage of Patients Referred to Quest Diagnostics Laboratories for Drug Testing by Their Physicians Testing Positive and Negative for Drugs Prescribed for Them, 2012. 102



Center for Substance Abuse Research, 2013








24

# Source Where Pain Relievers Were Obtained for Most Recent Misuse: Among People Aged 12 or Older Who Misused Pain Relievers in the Past Year; 2021



8.7 Million People Aged 12 or Older Who Misused Pain Relievers in the Past Year

Note: Respondents with unknown data for the Source for Most Recent Misuse or who reported Some Other Way but did not specify a valid way were excluded.











# What a Drug Test does NOT tell you:

#### **DRUG TESTS CANNOT:**

- Prove that a substance hasn't been taken
- •Identify every substance that may have been taken
- Detect if the patient is intoxicated/impaired
- •Rule out or diagnose a Substance Use Disorder!

https://www.erowid.org/











# What a Drug Test <u>DOES</u> tell you:

Drug tests measure if:

- Particular drug is in the patient's sample (urine, blood, saliva, etc)
- Drug is present at a specific point in time








## **Drug Testing in Different Contexts**

### Drug testing in different contexts











### Current Issues with UDS...

Research Letter

# Urine Drug Screening for Isolated Marijuana Use in Labor and Delivery Units

Alexandra Rubin, MD, Lydia Zhong, BA, Lauren Nacke, LCSW, MSW, Candice Woolfolk, PhD, MPH, Nandini Raghuraman, MD, MSCI, Ebony Carter, MD, MPH, and Jeannie Kelly, MD, MS

Isolated marijuana use is frequently used as an indication for urine drug screening in labor and delivery units. We aimed to identify the results of urine drug screening in a labor and delivery unit for isolated marijuana use. This retrospective cohort study reviewed data from patients of isolated marijuana use as a criterion for urine drug screening thus appears limited in benefit but rife with inequitable potential to harm.

(Obstet Gynecol 2022;140:607–9) DOI: 10.1097/AOG.00000000000004930





**Title: URINE TOXICOLOGY TESTING** for Medical Indications in the Zuckerberg San Francisco General Birth Center and Nursery

Date(s) revised: 08/10/2021

#### **Purpose of Policy**

- 1. Minimize bias, discrimination, and punitive use of urine toxicology in caring for patients and families.
- Care for birthing people and infants exposed to substances putting them at high risk for needing specific clinical interventions.
- This policy is not intended to replace the clinical judgment of a substance use treatment team in using urine drug testing to monitor treatment. It is intended to guide screening outside the context of ongoing treatment.







# Clinical Decision Making

•Drug testing results are just **ONE** component










# Window of Detection for Various Sample Types

Exhibit 2-1. Window of Detection for Various Matrices



\*Very broad estimates that also depend on the substance, the amount and frequency of the substance taken, and other factors previously listed.

†As long as the patch is worn, usually 7 days.

‡7–10 days after use to the time passed to grow the length of hair, but may be limited to 6 months hair growth. However, most laboratories analyze the amount of hair equivalent to 3 months of growth.

Sources: Adapted from Cone (1997); Dasgupta (2008).

Each sample type has its own limitations and benefits; consult with a clinical pathologist or toxicologist to determine the best testing for your needs









## **Urine Drug Testing**

- Easy to collect, but requires a bathroom
- May be observed or unobserved
  - Observed does not necessarily prevent tampering
  - Observed urine collection may be distressing for some patients with a history of trauma (sexual trauma)
  - If using an observer, choose staff member of same gender
- Prone to tampering
  - Dilution
  - Addition of interfering substance
  - Substitution with another person's urine
- Options for testing for sample integrity
  - Temperature
  - pH
  - Specific gravity
- Standardized collection protocol









- 35 yo F reports taking her oxycodone daily. She presents for a urine drug screen:
- Explanation?
- Opiate (natural) vs. Opioid (synthetic)
  - Morphine, codeine, opium
  - Oxycodone, tramadol, buprenorphine, heroin, fentanyl


	Component	Ref Range & Units	3/23/20 1453
×	Amphetamines Screen, Ur	Not Applicable	<500 ng/mL
×	Barbiturates Screen, Ur	Not Applicable	<200 ng/mL
×	Benzodiazepines Screen, Urine	Not Applicable	<200 ng/mL
×	Cannabinoids Screen, Ur	Not Applicable	<20 ng/mL
×	Methadone Screen, Urine	Not Applicable	<300 ng/mL
×	Cocaine(Metab.)Screen, Urine	Not Applicable	<150 ng/mL
×	Opiates Screen, Ur	Not Applicable	<300 ng/mL







#### Opioid and Opiate Metabolism









## **Expected Results on UDS for Opioids**

Table. Expected Results on Urine Drug Screening (UDS) for Commonly Encountered Opiates, Semisynthetic Opioids, and Synthetic Opioids<sup>a</sup>

Substance	Significant metabolites	Detected by standard UDS?	Specialized UDS available?
Opiates (natural products fro	m the poppy plant, papaver somniferum)		
Morphine	Morphine-3-glucuronide, morphine-6-glucuronide	Yes <sup>b</sup>	NA
Codeine	Codeine-6-glucuronide, morphine, norcodeine, hydrocodone	Yes <sup>b</sup>	NA
Semisynthetic opioids (not n	aturally occurring but chemically derived from opiates)		
Heroin	6-Monoacetylmorphine, morphine	Yes <sup>b</sup>	NA
Hydrocodone	Norhydrocodone, hydromorphone, dihydrocodeine <sup>c</sup>	Sometimes <sup>b</sup>	Yes <sup>d</sup>
Hydromorphone	Hydromorphone-3-glucuronide	Sometimes <sup>b</sup>	Yes <sup>d</sup>
Oxycodone	Noroxycodone, oxymorphone	No	Yes <sup>d</sup>
Oxymorphone	Oxymorphone-3-glucuronide	No	Yes <sup>d</sup>
Buprenorphine	Norbuprenorphine, buprenorphine-3-glucuronide	No	Yes <sup>d</sup>
Synthetic opioids (synthesize	ed in a laboratory and structurally distinct from opiates)		
Fentanyl	Norfentanyl, despropionylfentanyl	No	Yes <sup>d</sup>
Methadone	2-Ethylidene-1,5-dimethyl-3,3-diphenylpyrrolidine (EDDP)	No	Yes <sup>d</sup>
Tramadol	N-Desmethyltramadol, O-desmethyltramadol	No	Yes <sup>d</sup>
Loperamide	N-Desmethyl-loperamide	No	No <sup>d</sup>
Miscellaneous (opioid natura	l product not belonging to the above categories)		
Mitragynine (Kratom)	7-Hydroxymitragynine	No	Yes <sup>d</sup>

Weiss ST, Chinn M, Veach L. Reconsidering Reliance on Confirmatory Drug Testing in a Patient With Repeated Positive Urine Drug Screen Results: A Teachable Moment. *JAMA Intern Med*. 2021;181(12):1637-1638.









•33 yo F presents for care. She has been using a variety of different CBD/THC products and is curious what might show up on a urine drug screen.



 $\Delta$ -8

**CBD** 
















### Cannabinoids

- 113 active cannabinoids in the cannabis plant
- Hemp, Marijuana, Hashish, Hash oil, edibles, synthetic
- 1990s THC potency ~4%-----2018 > 15%.
- People who use MJ < 18 yo, 4-7x more like to develop CUD</li>
- No FDA approved medications
- Some studies suggest cannabis causal factor for Schizophrenia
- FDA approved:
  - Dronabinol (Marinal)
  - Nabilone (Cesamet)
  - Cannabidiol (Epidiolex)



Delta-9-Tetrahydro

cannabinol

**Cannabis Characterization** 





- 25 yo M reports taking clonazepam daily
- Reports to clinic for routine monitoring










# BZD Confirmation Interpreting Urine Drug Screens

#### BZD metabolic pathways







- •44 yo reports doing well with oxycodone for pain management.
- •Presents to clinic, reports UDS will be +oxy.
- •UDS = +cocaine
- •Next Steps?









# How do you respond to results?



- •Tests provide information to guide treatment
  - Results are consistent (expected) or inconsistent (unexpected) with the rest of the clinical picture
- Patients may have anxiety about potential test results and may not feel comfortable talking about recent drug use
- •Consistent, compassionate, nonjudgmental and health-oriented approach will help to develop therapeutic alliance with the patient over time.










- •24 yo here for routine monitoring of ADHD prescribed stimulant.
- UDS+ morphine, "I'm just taking my Adderall!"

- **True** or **False**: Poppy seeds can lead to a positive urine drug screen for opiates?
- Answer: True
   (roll vs. raw poppy seed resulted in urinary morphine concentrations below 2,000 ng/mL)









- •25 yo with hx tobacco, cannabis use presents requesting Sudafed (pseudoephedrine) for chronic symptoms of allergic rhinitis.
- You notice they have lost 20 lbs since last visit.
- POC UDS+ amphetamines
- •Next Step?

	Component	Ref Range & Units	5/13/21 1522
×	Amphetamine Confirm	Cutoff: 25 ng/mL	4166
×	Phentermine	Cutoff: 25 ng/mL	Negative
×	Methamphetamine Con- firm, Ur	Cutoff: 25 ng/mL	>60000
×	Pseudoephedrine	Cutoff: 25 ng/mL	Negative
×	MDA	Cutoff: 25 ng/mL	Negative
×	MDMA Confirm	Cutoff: 25 ng/mL	Negative
×	Amphet Interp, Urine		Positive.







- •Hx PTSD, MDD, GAD is moving into a recovery house
- •Requesting UDS prior to entry into the house
- •What might we expect for:
  - Amphetamines:
    - bupropion, fluoxetine, propranolol, ranitidine, trazodone
  - Benzodiazepines:
    - sertraline
  - Buprenorphine:
    - tramadol, fluoxetine, doxepin, haloperidol, sertraline, risperidone
  - Methadone:
    - quetiapine, tramadol, diphenhydramine
  - Phencyclidine:
    - DXM, diphenhydramine, tramadol, venlafaxine
  - LSD:
    - amitriptyline









- •42 yo man returns to clinic for follow up
- •Reports restlessness, diaphoresis, body aches, insomnia, anxiety
- •Has been using a supplement from a local store

•UDS:

→ TOX, URINE	
Amphetamines, Urine POCT	NEGAT
Barbiturates, Urine POCT	NEGAT
Benzodiazepines, Urine POCT	NEGAT
Buprenorphine, Urine POCT	NEGAT
Cannabinoids, Urine POCT	PRESU
Cocaine, Urine POCT	NEGAT    ■
Methadone, Urine POCT	NEGAT
Methamphetamine, Urine POCT	NEGAT
Opiates, Urine POCT	NEGAT
Oxycodone, Urine POCT	NEGAT







# Case #8: Mitragyna speciosa (Kratom)

- Major alkaloid: Mitragynine
  - Low dose -> Stimulant-like effect (≤ 5g)
  - Higher doses -> Opioid-like effect (~15g)



• No controlled trials, similar to other opioids



Mostly case reports or case series



Kratom (Mitragynine), Screen and Confirmation, Urine

**TEST:** 791750 CPT: 80307

Test Includes

7-Hydroxymitragynine; mitragynine








- •44 yo presents to clinic
- •Hx alcohol use disorder and was recently asked to leave his recovery housing due to a +drug screen.
- •He denies illicit substance use

•Naltrexone -> noroxymorphone


https://pubmed.ncbi.nlm.nih.gov/31366308/








- •28 yo presents to clinic 9 days after starting buprenorphine-naloxone
- UDS+ Fentanyl
- •Patient denies use, is this possible?











#### Resources

http://eguideline.guidelinecentral.com/i/840070-drug-testing-pocket-guide/0?

- Part 1 http://www.youtube.com/watch?v=ag5BWxn 38I
- Part 2 <a href="https://www.youtube.com/watch?v=XNEEMrO0kdc">https://www.youtube.com/watch?v=XNEEMrO0kdc</a>
- **\*UNODC Early Warning Advisory (EWA) on New Psychoactive**Substances (NPS)
  - https://www.unodc.org/LSS/Home/NPS
- European Monitoring Centre For Drugs and Drug Addiction
  - https://www.emcdda.europa.eu/
- \*Pubchem
  - https://pubchem.ncbi.nlm.nih.gov/
- The Center for Forensic Science Research and Education (CFSRE): Novel Psychoactive Substance Discovery
  - https://www.npsdiscovery.org/
- \*Toxicology Investigators Consortium (ToxIC) Fentalog Study
  - https://www.toxicregistry.org/Fentanyl\_Analogs.html



# THE ASAM APPROPRIATE USE OF DRUG TESTING IN CLINICAL ADDICTION MEDICINE

#### Consultants:

Timothy Wiegand, MD, FACMT, FAACT, FASAM Associate Professor of Clinical Emergency Medicine University of Rochester Medical Center, Rochester, NY Marla D. Kushner, DO, FACOFP, DFASAM, FSAHM Clinical Assistant Professor Midwestern University, Chicago, IL



American Society of Addiction Medicine TREAT ADDICTION • SAVE LIVES http://www.ASAM.org



Thank you!

michael\_baca-atlas@med.unc.edu

